Cellectar Biosciences (CLRB) Competitors $4.72 -0.12 (-2.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.76 +0.04 (+0.74%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. XLO, AKTX, MAAQ, SNYR, RANI, DYAI, ESLA, RNTX, PMN, and BDRXShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Xilio Therapeutics (XLO), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Synergy CHC (SNYR), Rani Therapeutics (RANI), Dyadic International (DYAI), Estrella Immunopharma (ESLA), Rein Therapeutics (RNTX), Promis Neurosciences (PMN), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Its Competitors Xilio Therapeutics Akari Therapeutics Mana Capital Acquisition Synergy CHC Rani Therapeutics Dyadic International Estrella Immunopharma Rein Therapeutics Promis Neurosciences Biodexa Pharmaceuticals Xilio Therapeutics (NASDAQ:XLO) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Which has more risk and volatility, XLO or CLRB? Xilio Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Is XLO or CLRB more profitable? Cellectar Biosciences has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -585.54%. Xilio Therapeutics' return on equity of -262.69% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Xilio Therapeutics-585.54% -262.69% -64.01% Cellectar Biosciences N/A -619.70%-158.04% Do institutionals and insiders have more ownership in XLO or CLRB? 54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 5.2% of Xilio Therapeutics shares are owned by insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, XLO or CLRB? Cellectar Biosciences has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$6.34M5.31-$58.24M-$0.84-0.77Cellectar BiosciencesN/AN/A-$44.58M-$21.92-0.22 Do analysts rate XLO or CLRB? Xilio Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 515.38%. Cellectar Biosciences has a consensus price target of $375.00, suggesting a potential upside of 7,844.92%. Given Cellectar Biosciences' higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer XLO or CLRB? In the previous week, Xilio Therapeutics had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 2 mentions for Xilio Therapeutics and 0 mentions for Cellectar Biosciences. Xilio Therapeutics' average media sentiment score of 0.75 beat Cellectar Biosciences' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Xilio Therapeutics Positive Cellectar Biosciences Neutral SummaryXilio Therapeutics beats Cellectar Biosciences on 9 of the 14 factors compared between the two stocks. Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.76M$10.40B$5.47B$9.53BDividend YieldN/A2.02%4.74%4.08%P/E Ratio-0.2218.4228.6723.80Price / SalesN/A29.02422.3188.12Price / CashN/A22.3135.4557.96Price / Book0.533.478.275.55Net Income-$44.58M$234.77M$3.24B$259.03M7 Day Performance-7.27%-4.82%-3.63%-4.56%1 Month Performance-0.21%1.80%4.40%4.49%1 Year Performance-92.05%-12.51%25.97%18.05% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences2.6155 of 5 stars$4.72-2.5%$375.00+7,844.9%-92.4%$8.76MN/A-0.2210XLOXilio Therapeutics3.212 of 5 stars$0.68-2.1%$4.00+486.5%-31.6%$36.08M$6.34M0.0070News CoverageAKTXAkari Therapeutics2.6588 of 5 stars$1.14+1.3%$5.00+340.5%-73.1%$36.04MN/A0.009High Trading VolumeMAAQMana Capital AcquisitionN/A$4.39-4.2%N/A+875.0%$35.65MN/A0.001SNYRSynergy CHC3.8562 of 5 stars$3.72-1.8%$10.00+168.8%+3,260.0%$34.85M$34.83M0.0040Trending NewsRANIRani Therapeutics1.7374 of 5 stars$0.55+3.6%$7.33+1,231.2%-80.6%$33.63M$1.03M0.00110Upcoming EarningsShort Interest ↑DYAIDyadic International2.0499 of 5 stars$1.11+0.9%$6.00+440.5%-25.6%$33.10M$3.49M0.007News CoveragePositive NewsGap UpESLAEstrella Immunopharma3.0615 of 5 stars$0.92+1.1%$16.00+1,639.1%-51.2%$32.91MN/A0.00N/ARNTXRein TherapeuticsN/A$1.41-3.4%N/AN/A$32.34MN/A0.009Positive NewsPMNPromis Neurosciences2.3666 of 5 stars$0.90-8.8%$4.33+381.4%-46.8%$32.25MN/A0.005Upcoming EarningsShort Interest ↑Gap DownBDRXBiodexa Pharmaceuticals0.0971 of 5 stars$0.88flatN/AN/A$32.16M$470K0.0020News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies XLO Alternatives AKTX Alternatives MAAQ Alternatives SNYR Alternatives RANI Alternatives DYAI Alternatives ESLA Alternatives RNTX Alternatives PMN Alternatives BDRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLRB Stock Alerts